Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
August 05, 2019 08:05 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA

NORCROSS, Ga., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for...
May 28, 2019 09:05 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise

NORCROSS, Ga., May 28, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced its Rights Offering...
May 23, 2019 17:30 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering

NORCROSS, Ga., May 23, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported the Alternate Price...
May 10, 2019 08:05 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019

NORCROSS, Ga., May 10, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...
May 10, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update

Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29. Rights expire at 5:00 PM Eastern on May 23, 2019 ...
April 15, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement

NORCROSS, Ga., April 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key...
April 02, 2019 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

NORCROSS, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold...
March 22, 2019 10:19 ET | Source: Galectin Therapeutics Inc.

Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology

NORCROSS, Ga., March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins,...
March 06, 2019 08:03 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders

NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...